Individualizing Adjuvant Therapy in Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Node-Positive Breast Cancer-Reference-Cited by-同舟云学术

Individualizing Adjuvant Therapy in Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Node-Positive Breast Cancer

Published:2022-04 Issue:4 Volume:18 Page:247-251
ISSN:2688-1527
Container-title:JCO Oncology Practice
language:en
Short-container-title:JCO Oncology Practice

Author:

Gogineni Keerthi¹^ORCID,Kalinsky Kevin¹

Affiliation:

1. Emory School of Medicine, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Oncology (nursing),Health Policy,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/OP.21.00780

Reference26 articles.

1. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

2. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

3. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

4. The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study;BMC Cancer;2024-08-08

2. Advances in personalized radiotherapy;BMC Cancer;2024-05-03

3. Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review;European Journal of Cancer;2022-09